TABLE 1.

Characteristics of HCV infection in patients with and without cancer

Characteristic	HCV Infection in Patients with Cancer	HCV Infection in Patients without Cancer
Findings on serologic assays for HCV antibodies	False-negative results possible (negative findings on screening for HCV antibodies with detectable HCV RNA in serum)	Reliable
Risk of development of fibrosis progression and early cirrhosis	High, particularly in HCT recipients	Low
Viral reactivation	Reported after certain types of cancer treatment	Uncommon in patients without immunosuppression
Standard-of-care anti-HCV therapy	Not defined	Well defined
Rate of sustained virologic response after treatment with DAAs	High	High
Risk of drug-drug interactions with DAAs	High	Low to moderate
Use of DAAs in patients with decompensated cirrhosis	Potentially contraindicated	Recommended but to be managed by providers with expertise in that condition, ideally in a liver transplant center
Provision of care	Frequently requires a transdisciplinary team	Frequently managed by single provider

DAA, direct-acting antiviral; HCT, hematopoietic cell transplant; HCV, hepatitis C virus